Symbols / CBIO Stock $18.00 -2.44% Crescent Biopharma, Inc.
CBIO (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteCrescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Ratings
Current target
$18.00
Low
$27.00
High
$35.00
Mean
$31.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-06-01 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2026-03-02 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2026-01-21 | init | Guggenheim | — → Buy | $35 |
| 2025-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-08-25 | init | Jefferies | — → Buy | $26 |
| 2025-08-11 | init | HC Wainwright & Co. | — → Buy | $25 |
| 2025-07-14 | init | Wedbush | — → Outperform | $27 |
| 2025-06-25 | init | Stifel | — → Buy | $28 |
- Crescent Biopharma (CBIO) director receives grant of 11,050 stock options at $17.01 - Stock Titan Wed, 03 Jun 2026 23
- Cancer-focused biotech joins Jefferies and Goldman investor talks - Stock Titan ue, 02 Jun 2026 20
- $CBIO stock is up 15% today. Here's what we see in our data. - Quiver Quantitative hu, 19 Feb 2026 08
- Crescent Biopharma Stock Surges 86%, With A 7-Day Winning Spree - Trefis Fri, 03 Apr 2026 07
- symbol__ Stock Quote Price and Forecast - CNN Wed, 18 Jun 2025 19
- Director at Crescent Biopharma (CBIO) receives option grant for 11,050 shares - Stock Titan Wed, 03 Jun 2026 23
- CRESCENT BIOPHARMA, INC. ($CBIO) CEO & Director 2025 Pay Revealed - Quiver Quantitative ue, 21 Apr 2026 07
- Crescent Biopharma Stock On Fire: Up 86% With 7-Day Winning Streak - Trefis hu, 02 Apr 2026 07
- Crescent Biopharma director granted 11,050 options | CBIO Insider Trading - Stock Titan Wed, 03 Jun 2026 23
- CBIO | Crescent Biopharma, Inc. Common Insider Trading - Quiver Quantitative Sun, 14 Dec 2025 01
- Fairmount-linked director awarded 11,050 CBIO options at $17.01 exercise price - Stock Titan Wed, 03 Jun 2026 23
- Crescent Biopharma (CBIO) investors back directors, auditor and annual say-on-pay - Stock Titan Wed, 03 Jun 2026 13
- Two new Crescent Biopharma hires get options at $21.47 a share - Stock Titan Fri, 29 May 2026 20
- Crescent lines up 2027 cancer trial readouts with cash into 2028 - Stock Titan Wed, 29 Apr 2026 07
- Crescent cancer trial takes CR-001 to ASCO 2026, first data expected in 2027 - Stock Titan hu, 21 May 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Total Revenue |
|
10.84
|
| Operating Revenue |
|
10.84
|
| Operating Expense |
|
163.48
|
| Research And Development |
|
138.09
|
| Selling General And Administration |
|
25.39
|
| General And Administrative Expense |
|
25.39
|
| Salaries And Wages |
|
14.56
|
| Other Gand A |
|
10.83
|
| Total Expenses |
|
163.48
|
| Operating Income |
|
-152.63
|
| Total Operating Income As Reported |
|
-152.63
|
| EBITDA |
|
-149.67
|
| Normalized EBITDA |
|
-149.67
|
| Reconciled Depreciation |
|
0.08
|
| EBIT |
|
-149.76
|
| Net Income |
|
-153.94
|
| Pretax Income |
|
-151.94
|
| Net Non Operating Interest Income Expense |
|
0.69
|
| Interest Expense Non Operating |
|
2.19
|
| Net Interest Income |
|
0.69
|
| Interest Expense |
|
2.19
|
| Interest Income Non Operating |
|
2.88
|
| Interest Income |
|
2.88
|
| Tax Provision |
|
2.00
|
| Tax Rate For Calcs |
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-153.94
|
| Net Income From Continuing Operation Net Minority Interest |
|
-153.94
|
| Net Income From Continuing And Discontinued Operation |
|
-153.94
|
| Net Income Continuous Operations |
|
-153.94
|
| Normalized Income |
|
-153.94
|
| Net Income Common Stockholders |
|
-153.94
|
| Diluted EPS |
|
-12.81
|
| Basic EPS |
|
-12.81
|
| Basic Average Shares |
|
10.41
|
| Diluted Average Shares |
|
10.41
|
| Diluted NI Availto Com Stockholders |
|
-153.94
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets |
|
240.29
+574.66%
|
35.62
|
| Current Assets |
|
236.66
+579.96%
|
34.80
|
| Cash Cash Equivalents And Short Term Investments |
|
213.19
+513.22%
|
34.77
|
| Cash And Cash Equivalents |
|
213.19
+513.22%
|
34.77
|
| Cash Financial |
|
213.19
+513.22%
|
34.77
|
| Receivables |
|
18.00
|
0.00
|
| Accounts Receivable |
|
18.00
|
0.00
|
| Prepaid Assets |
|
4.18
|
0.00
|
| Other Current Assets |
|
1.28
+3263.16%
|
0.04
|
| Total Non Current Assets |
|
3.64
+347.48%
|
0.81
|
| Net PPE |
|
2.31
|
0.00
|
| Gross PPE |
|
2.31
|
0.00
|
| Other Properties |
|
2.31
|
—
|
| Non Current Deferred Assets |
|
—
|
0.81
|
| Other Non Current Assets |
|
1.32
+62.73%
|
0.81
|
| Total Liabilities Net Minority Interest |
|
37.28
-27.04%
|
51.10
|
| Current Liabilities |
|
36.07
+275.20%
|
9.61
|
| Payables And Accrued Expenses |
|
21.36
+123.95%
|
9.54
|
| Payables |
|
18.14
+147.50%
|
7.33
|
| Accounts Payable |
|
10.00
+9242.99%
|
0.11
|
| Current Accrued Expenses |
|
3.22
+45.84%
|
2.21
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
5.12
+34040.00%
|
0.01
|
| Total Tax Payable |
|
8.00
|
0.00
|
| Current Debt And Capital Lease Obligation |
|
0.43
|
—
|
| Current Capital Lease Obligation |
|
0.43
|
0.00
|
| Current Deferred Liabilities |
|
4.16
|
0.00
|
| Current Deferred Revenue |
|
4.16
|
0.00
|
| Other Current Liabilities |
|
5.00
+8096.72%
|
0.06
|
| Total Non Current Liabilities Net Minority Interest |
|
1.21
-97.09%
|
41.48
|
| Long Term Debt And Capital Lease Obligation |
|
1.21
-96.77%
|
37.48
|
| Long Term Debt |
|
—
|
37.48
|
| Long Term Capital Lease Obligation |
|
1.21
|
0.00
|
| Preferred Securities Outside Stock Equity |
|
0.00
-100.00%
|
4.00
|
| Stockholders Equity |
|
203.01
+1411.53%
|
-15.48
|
| Common Stock Equity |
|
199.01
+1385.69%
|
-15.48
|
| Capital Stock |
|
4.03
+402700.00%
|
0.00
|
| Common Stock |
|
0.03
+2700.00%
|
0.00
|
| Preferred Stock |
|
4.00
|
0.00
|
| Share Issued |
|
30.45
+56.14%
|
19.50
|
| Ordinary Shares Number |
|
30.45
+56.14%
|
19.50
|
| Additional Paid In Capital |
|
370.79
+15433.85%
|
2.39
|
| Retained Earnings |
|
-171.81
-861.60%
|
-17.87
|
| Total Equity Gross Minority Interest |
|
203.01
+1411.53%
|
-15.48
|
| Total Capitalization |
|
203.01
+822.66%
|
22.00
|
| Working Capital |
|
200.58
+696.28%
|
25.19
|
| Invested Capital |
|
199.01
+804.48%
|
22.00
|
| Total Debt |
|
1.64
-95.61%
|
37.48
|
| Net Debt |
|
—
|
2.72
|
| Capital Lease Obligations |
|
1.64
|
0.00
|
| Net Tangible Assets |
|
203.01
+1411.53%
|
-15.48
|
| Tangible Book Value |
|
199.01
+1385.69%
|
-15.48
|
| Dueto Related Parties Current |
|
0.14
-98.06%
|
7.22
|
| Interest Payable |
|
0.00
-100.00%
|
0.85
|
| Preferred Stock Equity |
|
4.00
|
—
|
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Operating Cash Flow |
|
-71.53
|
| Cash Flow From Continuing Operating Activities |
|
-71.53
|
| Net Income From Continuing Operations |
|
-153.94
|
| Depreciation Amortization Depletion |
|
0.08
|
| Depreciation |
|
0.08
|
| Depreciation And Amortization |
|
0.08
|
| Other Non Cash Items |
|
82.40
|
| Stock Based Compensation |
|
13.30
|
| Change In Working Capital |
|
-13.37
|
| Change In Receivables |
|
-18.00
|
| Changes In Account Receivables |
|
-18.00
|
| Change In Prepaid Assets |
|
-5.01
|
| Change In Payables And Accrued Expense |
|
0.36
|
| Change In Accrued Expense |
|
5.36
|
| Change In Payable |
|
-5.00
|
| Change In Account Payable |
|
2.08
|
| Change In Other Working Capital |
|
4.32
|
| Change In Other Current Liabilities |
|
4.96
|
| Investing Cash Flow |
|
-72.92
|
| Cash Flow From Continuing Investing Activities |
|
-72.92
|
| Net PPE Purchase And Sale |
|
-0.92
|
| Purchase Of PPE |
|
-0.92
|
| Capital Expenditure |
|
-72.92
|
| Net Intangibles Purchase And Sale |
|
-72.00
|
| Purchase Of Intangibles |
|
-72.00
|
| Financing Cash Flow |
|
322.98
|
| Cash Flow From Continuing Financing Activities |
|
322.98
|
| Net Issuance Payments Of Debt |
|
0.00
|
| Issuance Of Debt |
|
0.00
|
| Long Term Debt Issuance |
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
|
| Net Common Stock Issuance |
|
321.71
|
| Common Stock Payments |
|
-0.18
|
| Repurchase Of Capital Stock |
|
-0.18
|
| Proceeds From Stock Option Exercised |
|
0.01
|
| Net Other Financing Charges |
|
1.27
|
| Changes In Cash |
|
178.53
|
| Beginning Cash Position |
|
34.77
|
| End Cash Position |
|
213.30
|
| Free Cash Flow |
|
-144.45
|
| Common Stock Issuance |
|
321.89
|
| Issuance Of Capital Stock |
|
321.89
|
| Net Preferred Stock Issuance |
|
0.00
|
| Preferred Stock Issuance |
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-06-03 View
- 42026-06-03 View
- 42026-06-03 View
- 42026-06-03 View
- 42026-06-03 View
- 8-K2026-06-03 View
- 8-K2026-04-29 View
- 10-Q2026-04-29 View
- 8-K2026-02-26 View
- 10-K2026-02-26 View
- 42025-12-17 View
- 42025-12-17 View
- 42025-12-17 View
- 42025-12-17 View
- 42025-12-17 View
- 42025-12-17 View
- 42025-12-17 View
- 42025-12-17 View
- 42025-12-10 View
- 42025-12-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|